CMN Weekly (19 November 2021) - Your Weekly CRISPR...
Nov. 19, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Celularity
Main focus: Next generation cellular therapeutics
Company stage: Clinical
Diseases: B-cell malignancies, gastric cancer, other undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:CELU)
Location: New Jersey, USA
Website: https://celularity.com/
Pipeline: https://celularity.com/pipeline/
Celularity develops natural kill (NK)- and T-cell based therapies from placenta-derived cell populations. The company primarily uses CRISPR for genetic modification of its T cell based-products. Placental-derived CAR-T cells are mostly naïve (CD45RA+), expand readily ex vivo, express markers of stem cell memory, and have lower expression of effector or exhaustion markers, allowing for greater proliferative potential of these cells in vivo. The company is advancing multiple programmes, none of which are at clinical stage as of yet.
